Research Bridge Partners is a non-profit organization based in Austin, Texas, dedicated to enhancing the societal and economic impact of research universities in the mid-continent region of the United States. Founded by Isaac Barchas and Reid Hoffman, the organization connects university innovators with commercialization resources across the country. It manages a seed fund that exclusively accepts program-related investments from other charitable entities to support its tax-exempt charitable, educational, and scientific objectives. By focusing on strategic startup creation, Research Bridge Partners aims to advance scientific research in the public interest, ensuring that innovations from mid-continent universities contribute to broader societal benefits.
Tetricus Labs is a precision psychiatry company focused on improving mental health treatment through advanced AI computational neuroscience. The company has developed a healthcare platform designed to deliver accurate and individualized diagnoses for patients with psychiatric conditions. By leveraging cutting-edge technology, Tetricus Labs aims to provide tailored treatment recommendations, ensuring that each patient receives the appropriate care for their specific needs.
UT Southwestern Medical Center
Grant in 2023
The UT Southwestern Medical Center provides patient care, research facilities, and academic medical centers. They offer cutting-edge therapies, treatments, and first-rate specialized care.
Asalyxa Bio
Seed Round in 2021
Asalyxa Bio, Inc. is a drug development company based in Southfield, Michigan, specializing in novel therapeutics aimed at addressing significant unmet medical needs resulting from the dysregulation of immune signaling. The company has developed a platform technology that facilitates the targeted delivery of both existing and innovative drugs directly into over-reactive immune cells. This approach is particularly focused on combating severe neutrophil-mediated diseases, including conditions such as Covid-19, and has applications across a broad range of disease areas. By leveraging this technology, Asalyxa Bio aims to enhance treatment options and improve patient outcomes in various therapeutic contexts.
Novosteo
Seed Round in 2019
Novosteo Inc., founded in 2017 and located in West Lafayette, Indiana, focuses on developing and manufacturing innovative drugs aimed at treating bone injuries and diseases. The company addresses significant health issues related to bone fractures, including morbidity, mortality, and reduced mobility and productivity. Its scientific co-founders from Purdue University have pioneered a proprietary chemistry approach that targets bone regeneration. Novosteo's drug discovery platform features a range of fracture-targeted therapeutics designed to deliver healing agents directly to fracture sites, enhancing the healing process and alleviating the debilitating effects associated with bone injuries. Through its novel biologics, Novosteo aims to improve patient outcomes and quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.